The core activity of Jantar GmbH is the development of pharmaceutical products, particularly research and development (R&D) of medications for the treatment of rhinosinusitis, specifically with the active ingredient JT-1 for nasal spray application.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
✓ Offered3
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of Dicholinsuccinate for chronic rhinosinusitis
Preclinical development, active substance synthesis, drug product manufacturing, analytics, stability and toxicology for Dicholinsuccinate as a nasal spray for chronic rhinosinusitis.
Clinical development and Phase III studies
Proof-of-concept studies in patients with chronic rhinosinusitis as well as planned controlled, randomized Phase III study as a basis for marketing authorization.
Licensing and cooperation for consumer health partners
Search for an international partner for a licensing and cooperation agreement to continue the clinical and commercial development of a nasal spray.
Comparisons
Jantar GmbH in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank Jantar GmbH by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once Jantar GmbH has claimed this profile, we'll publish editorial articles and case studies here together.